Skip to main content

Table 2 Clinical manifestation

From: Study on clinical and biological characteristics of ameloblastic carcinoma

Patient no Location Sex/year S/C/R (times) Course (year) Follow-up time (month) R-t/Treatment BRAF-V600E Type
1 Maxilla F/53 2/0/0 1 32 1/Conservative + Primary
2 Mandible M/64 1/3/0 0.5 26 0/Radical + ND + C +  
3 Mandible F/63 1/0/0 20 82 0/Radical + ND + RC NP  
4 Mandible M/52 2/0/0 0.5 21 1/Conservative +  
5 Mandible F/66 2/0/0 18 40 1/Radical + RC NP Secondary
6 Mandible F/60 2/0/0 4.5 36 1/Conservative NP  
7 Mandible M/43 1/2/0 18 14 0/Radical + C NP  
8 Mandible F/28 4/0/0 8 21 2/Conservative; 1/Radical NP  
9 Mandible M/61 4/0/0 2.3 69 1/Radical + RC;1/Conservative; 1/Radical +  
10 Mandible F/75 3/0/0 5 78 1/Conservative; 1/Radical NP  
11 Mandible M/25 2/0/1 1.5 69 1/Radical + RC;1/Conservative +  
12 Mandible M/24 3/0/0 6 52 1/Conservative;1/Radical NP  
13 Maxilla F/68 8/0/1 41 54 6/Conservative;1/Radical NP  
14 Mandible M/51 1/0/0 13 67 0/Radical + RC NP  
15 Mandible M/36 4/1/0 15 5 3/Conservative NP  
  1. F Female; M Male; S Surgery; C Chemotherapy; R Radiotherapy; R-t Recurrence-times; RC Reconstruction; ND Neck dissection; NP Not performed